EU Publishes MDCG 2020-16 rev.5: IVD Classification Guidance Revision Addresses Rule 7 Quality Control Materials Only

EU Publishes IVD Classification Guidance Revision MDCG 2020-16 rev.5 in September 2026: Rule 7 Quality Control Materials Only

Published: 30 September 2026, 15:27  |  Category: News and Technical Guidance

Event and Source Text

On 9 September 2026, the European Commission's Medical Device Coordination Group (MDCG) published MDCG 2020-16 rev.5, the latest revision of its guidance on the classification of in vitro diagnostic medical devices (IVDs). The guidance corresponds to Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR) and explains how the classification rules set out in Annex VIII to the IVDR are to be applied. It is addressed to manufacturers, notified bodies and healthcare institutions, and supports the classification of IVDs before they are placed on the market or put into service in the European Union.

What This Revision Changes

The change table on the cover page of the guidance shows that the rev.5 revision concerns Rule 7 only, namely "clarification of the justification and revision of the examples". The same table lists the scope of previous revisions; rev.4, dated March 2025, covered Rule 1, Rule 3(m), Rule 4(a), Rule 6 and editorial adjustments to the annexes. In other words, rev.5 is a targeted update addressing Rule 7, and the remaining classification rules were not amended by this revision.

What Rule 7 Covers

According to the main text of the guidance, Rule 7 applies to quality control materials that the manufacturer intends to be used for an IVD procedure and for which no assigned value has been established. Where the instructions for use include a parameter range provided by the manufacturer for such control materials, that range serves as a reference only; the target values used by the laboratory in routine practice are established by the medical laboratory itself, rather than being the indicative values provided by the manufacturer.

To avoid confusion with quality control materials supplied by reagent or instrument manufacturers, standalone QC materials must state clearly in their instructions for use that their intended purpose is limited to monitoring the validity of the laboratory's examination procedure, and that they cannot replace the mandatory quality control materials used to verify the performance of the IVD itself. Unless another rule applies, such unassigned control materials are classified as Class B under Rule 7.

Boundaries to Be Distinguished

The guidance also states that control materials to which the manufacturer has assigned a quantitative or qualitative value, including controls for the validity of a test kit, must be classified under Implementing Rule 1.6 and are not covered by Rule 7. The guidance further notes that, in accordance with Article 1(3)(c) and (d) of the IVDR, internationally certified reference materials and materials used in external quality assessment schemes are not IVDs. Understanding this distinction is key to determining whether a quality control material falls under Rule 7 or Implementing Rule 1.6, and it directly affects how the technical documentation and instructions for use are drafted.

Nature of the Document and Key Dates

MDCG 2020-16 is a guidance document drafted jointly by Member State competent authorities, Commission services, notified bodies and industry experts, and endorsed by the MDCG. It is not legally binding; only the interpretation of EU law given by the Court of Justice of the European Union is binding. The examples contained in the document are illustrative only and do not constitute an exhaustive list. The official publication date of this revision is 9 September 2026.

AIMEILI Regulatory Interpretation

Rev.5 is a narrowly scoped update rather than a comprehensive revision of the IVD classification framework. For manufacturers of quality control materials, its practical significance lies in the sharper articulation of the boundary between Rule 7 and Implementing Rule 1.6. The central criterion is the presence or absence of an assigned value: a manufacturer-assigned quantitative or qualitative value pushes a control material into Rule 1.6, whereas unassigned controls intended for IVD procedures fall under Rule 7 and are classified as Class B absent another applicable rule.

Several points deserve attention in practice:

• Assigned value is decisive. The classification outcome depends less on the product name than on whether the manufacturer assigns a value and how that value is presented. Claiming a value in the instructions for use can move a product out of Rule 7.
• Intended purpose wording matters. Standalone QC materials must limit their stated intended purpose to monitoring the validity of the laboratory's examination procedure and must expressly state that they do not replace mandatory controls used to verify IVD performance.
• Exclusions must be observed. Certified reference materials and external quality assessment (EQA/PT) materials fall outside the definition of an IVD under Article 1(3)(c) and (d) of the IVDR and therefore are not classified under Annex VIII at all.
• Non-binding status. The guidance is not legally binding, but it reflects the coordinated position of MDCG members and notified bodies and is treated as the practical reference for conformity assessment in the EU market.

Business Impact

• Classification and conformity assessment route. Confirming Rule 7 classification as Class B determines whether the manufacturer can rely on the self-declaration route with a quality management system and technical documentation assessment, or must involve a notified body under the applicable conformity assessment procedure.
• Instructions for use and labelling updates. Existing standalone QC product labelling may need to be revised to align with the clarifications on intended purpose and the statement that these materials do not substitute for mandatory IVD performance controls.
• Technical documentation review. The classification justification should explicitly address the assigned-value question and cite the applicable rule, with the reasoning documented so it can withstand scrutiny by a notified body.
• Portfolio re-assessment. Manufacturers with both unassigned controls and value-assigned or kit-validity controls in their portfolio should map each product to the correct rule, since a single product line may span Rule 7 and Implementing Rule 1.6.
• Watch for further updates. Because the guidance is non-binding and may change with subsequent official updates, classification decisions should be revisited when new revisions are published.

Sources and Verification

Source: European Commission — Medical Device Coordination Group (MDCG), MDCG 2020-16 rev.5, "Guidance on Classification Rules for In Vitro Diagnostic Medical Devices under Regulation (EU) 2017/746", version dated September 2026, official publication date 9 September 2026.

• European Commission — Medical Device Coordination Group (MDCG), official announcement: https://health.europa.eu/latest-updates/mdcg-2020-16-rev5-guidance-classification-rules-vitro-diagnostic-medical-devices-under-regulation-eu-2026-09-09_en (2026-09-09)
• European Commission — MDCG 2020-16 rev.5 guidance PDF: https://health.europa.eu/document/download/12f9756a-1e0d-4aed-9783-d948553f1705_en?filename=md_mdcg_2020_guidance_classification_ivd-md_en.pdf
• European Commission — MDCG endorsed documents and other guidance: https://health.europa.eu/medical-devices-sector/new-regulations/guidance-mdcg-endorsed-documents-and-other-guidance_en

Scope of verification and access date: The Commission announcement page, the guidance PDF (cover-page change table and the Rule 7 section) and the MDCG guidance index page were reviewed; access date 30 September 2026. The justification and examples for Rule 7, and the record that rev.5 concerns Rule 7 only, are taken from the original text of the guidance.

Applicability note: This article is an interpretation of a publicly available regulatory guidance and does not constitute a conclusion or undertaking with respect to any specific product, company or registration application. The official text prevails. Guidance is not legally binding and may change with subsequent official updates.